SOXN Inhibitors
SOXN inhibitors encompass a diverse range of compounds that execute their inhibitory function through various biochemical pathways. The downregulation of the hedgehog signaling pathway by certain inhibitors leads to a decrease in the transcriptional activity of SOXN, which is integral to this pathway, thus attenuating its functional role. Similarly, the blockade of the PI3K/Akt pathway by specific inhibitors can curtail the downstream effects that are regulated by SOXN, which includes critical cellular processes such as differentiation and proliferation. Furthermore, compounds that inhibit the MEK enzyme disrupt the ERK pathway, a signaling cascade with which SOXN is involved, therefore likely diminishing its activity. Additional inhibitors targeting the Wnt/β-catenin pathway interfere with signaling mechanisms that modulate SOXN function, resulting in its decreased activity.
Another set of inhibitors acts on the cell cycle and related signaling pathways to modulate SOXN activity. Inhibitors that target cyclin-dependent kinases can inhibit cell cycle progression, which is crucial for the roles that SOXN plays in cell differentiation and proliferation. Inhibition of the TGF-β pathway also indirectly impacts SOXN's function, given its involvement in this signaling route. Molecules that inhibit the γ-secretase enzyme affect Notch signaling, a pathway wherein SOXN is active, thus leading to a reduction in its functional activity. In addition, agents that inhibit mTOR, CDK4/6, and the HIF pathway also contribute to the indirect inhibition of SOXN by influencing cellular growth, division, and hypoxia-mediated processes, respectively, which are all processes where SOXN is known to have a regulatory role.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $92.00 $204.00 | 19 | |
This hedgehog signaling pathway inhibitor downregulates the pathway, which SOXN is known to be a part of, thus reducing its transcriptional activity and resulting in decreased functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that impedes the PI3K/Akt pathway. SOXN activity is linked to this pathway, and inhibition can reduce its downstream effects, including cellular processes that SOXN regulates. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An inhibitor of MEK, which subsequently disrupts the ERK pathway. As SOXN is involved in this pathway, inhibition would likely decrease SOXN's functional activity through this route. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
This compound interferes with the Wnt/β-catenin pathway, indirectly leading to reduced activity of proteins like SOXN that are modulated by this pathway. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
A cyclin-dependent kinase inhibitor, which could inhibit cell cycle progression, potentially reducing the activity of SOXN which is implicated in cell differentiation and proliferation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
By inhibiting MEK1/2, U0126 impacts the MAPK/ERK pathway, and thus could decrease SOXN activity indirectly as it is associated with these signaling cascades. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
This inhibitor targets the TGF-β pathway, which can have downstream effects on the functional activity of SOXN, as it is influenced by this signaling route. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $99.00 $335.00 $836.00 $2099.00 | 47 | |
An inhibitor of the γ-secretase enzyme, impacting Notch signaling. Since SOXN operates within the realm of pathways affected by Notch, DAPT can decrease SOXN activity by this mechanism. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $35.00 $115.00 $515.00 | 26 | |
A tankyrase inhibitor that stabilizes axin and inhibits the Wnt pathway. Given SOXN's involvement in this pathway, its activity would likely be reduced by this inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
As an mTOR inhibitor, Rapamycin influences cellular growth and proliferation pathways, which could indirectly inhibit SOXN activity due to its role in these processes. | ||||||